



Gossamer Bio Announces Participation in the Guggenheim Healthcare Talks Neuro/Immunology Day

November 14, 2019

SAN DIEGO--(BUSINESS WIRE)--Nov. 14, 2019-- [Gossamer Bio, Inc.](#) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will participate in a fireside chat at the Guggenheim Healthcare Talks Neuro/Immunology Day on Monday, November 18 at 1:00 p.m. ET.

A live webcast of the presentation will be available on the "Events and Presentations" page in the "Investors" section of the company's website at <https://ir.gossamerbio.com>. A replay of the webcast will be archived on the company's website for 90 days following the presentation.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191114005228/en/>

Source: Gossamer Bio

For Investors:

Argot Partners
Tel 212.600.1902
gossamerbio@argotpartners.com

For Media:

Argot Partners
David Rosen
Tel 212.600.1902
david.rosen@argotpartners.com